Beta Bionics raised $60M in a Series E funding round led by Wellington Management to support the commercialization of the iLet bionic pancreas.
Beta Bionics raised $60M in a Series E funding round led by Wellington Management to support the commercialization of the iLet bionic pancreas.
11/14/24, 12:25 AM
Location
concordMoney raised
$60 million
Industry
biotechnology
Round Type
series e
Investors
Marshall Wace, Perceptive Advisors, Omega Funds, Soleus Capital, Sands Capital, Rtw Investments, Eventide Asset Management Llc, Wellington Management
Beta Bionics has closed a Series E preferred stock financing round worth a total of $60 million. The funding will support the expanded commercialization of its iLet bionic pancreas and product pipeline development.
Company Info
Location
300 baker avenue, suite 301
concord, massachusetts, united states
Additional Info
Beta Bionics is a commercial stage medical technology company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWDs) by utilizing advanced adaptive algorithms to simplify and improve the treatment of their disease. The iLet Bionic Pancreas is the first FDA-cleared autonomous insulin delivery device in the market and offers the potential to substantially improve overall outcomes across broad populations of PWDs.